Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | ACACB | O00763 | 10/20 | 0.49 |
| ▸ | ACACA | Q13085 | 6/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1204998 | 1.00 | KMT2A (0.51) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL1204996 | 1.00 | KMT2A (0.51) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL190838 | 0.93 | KMT2A (0.56) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL3816616 | 0.93 | KMT2A (0.56) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL3942686 | 0.93 | KMT2A (0.56) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL4377073 | 0.93 | KMT2A (0.56) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL17235806 | 0.90 | KMT2A (0.46) | KMT2ADRD2ACACBACACAEPHX1 | |
| Bicarbonate SCHEMBL1580718 | 0.89 | KMT2A (0.57) | KMT2ADRD2ACACBACACAEPHX1 | |
| Formaldehyde SCHEMBL28082239 | 0.89 | KMT2A (0.54) | KMT2ADRD2ACACBACACAEPHX1 | |
| SCHEMBL3945277 | 0.86 | KMT2A (0.51) | KMT2ADRD2ACACBACACAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC | 2023-10-05 | — | — | US | disclosed |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2023-05-16 | — | — | US | disclosed |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2022-06-02 | — | — | US | disclosed |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-09-28 | — | — | US | disclosed |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | VTV THERAPEUTICS LLC (US) | 2021-01-12 | — | — | US | disclosed |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | VTVX HOLDINGS II LLC | 2020-05-14 | — | — | US | disclosed |
| WO-2011103018-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011080510-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011035159-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-24 | — | — | WO | disclosed |
| US-20100298323-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100160322-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
| EP-2190824-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | Wyeth a Corporation of the State of Delaware (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009026326-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2009026319-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12091407-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | KMT2A 3620/4885DRD2 3974/4885ACACB 2088/4885 |
| US-20220169641-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | KMT2A 3620/4885DRD2 3974/4885ACACB 2088/4885 |
| US-11130753-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | KMT2A 3620/4885DRD2 3974/4885ACACB 2088/4885 |
| US-20110201604-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | HMOX2, HMOX1, PTGS2 | KMT2A 3250/4885DRD2 4460/4885ACACB 1695/4885 |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | KMT2A 1081/4885DRD2 4210/4885ACACB 59/4885 |
| US-20230312548-A1 | SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLS, HMOX2, REN | KMT2A 3465/4885DRD2 3763/4885ACACB 2577/4885 |
| US-20100298323-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | KMT2A 3558/4885DRD2 4630/4885ACACB 1002/4885 |
| US-11649230-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GLS, HMOX2, REN | KMT2A 3620/4885DRD2 3974/4885ACACB 2088/4885 |
| US-20200148673-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GOT2, GLS2, PYGL | KMT2A 3080/4885DRD2 4595/4885ACACB 105/4885 |
| US-10889580-B2 | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | GOT2, GLS2, PYGL | KMT2A 3080/4885DRD2 4595/4885ACACB 105/4885 |
| US-20100160322-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | KMT2A 3558/4885DRD2 4630/4885ACACB 1002/4885 |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | KMT2A 4198/4885DRD2 3466/4885ACACB 2863/4885 |
| US-20210002268-A1 | Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLS, HMOX2, REN | KMT2A 3620/4885DRD2 3974/4885ACACB 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.